恒瑞医药：泽美妥司他片获药品注册批准

Group 1 - The company Heng Rui Medicine (600276) has received conditional approval from the National Medical Products Administration for its self-developed innovative drug, Zemeituosita Tablets (SHR2554), for adult patients with relapsed or refractory peripheral T-cell lymphoma (R/RPTCL) who have previously undergone at least one line of systemic therapy [1] - Zemeituosita Tablets is the first self-developed EZH2 inhibitor in China [1]